What is OxThera?
OxThera, established in 2005 and based in Stockholm, Sweden, is a biopharmaceutical firm dedicated to developing treatments for Primary and Secondary Hyperoxaluria. The company's proprietary technology focuses on utilizing bacteria and enzymes to combat this condition. OxThera's intellectual property portfolio includes global patents for its innovative compositions and therapeutic approaches. The company is currently in the late stages of clinical development for its product candidates, positioning it for potential market entry and addressing a critical unmet medical need in kidney stone disease.
How much funding has OxThera raised?
OxThera has raised a total of $44.6M across 2 funding rounds:
Unspecified
$10.6M
Private Equity
$33.9M
Unspecified (2014): $10.6M with participation from Kurma Partners, IDInvest Partners, and Mayo Clinic
Private Equity (2016): $33.9M led by Industrifonden, Idinvest Partners, Life Sciences Partners, Sunstone Capital, KURMA PARTNERS, and Ysios Capital
Key Investors in OxThera
Kurma Partners
Kurma Partners is a European venture capital firm specializing in healthcare and biotechnology, investing across various stages from inception to expansion. They focus on transforming scientific discoveries into advanced medical solutions for severe diseases.
Industrifonden
Industrifonden is a Swedish venture capital fund that backs scalable innovations in deep tech and life sciences, aiming to improve society through breakthrough technologies and science.
Life Sciences Partners
Life Sciences Partners (LSP) is a European venture capital firm dedicated to investing in innovative biotechnology companies. They focus on advancing novel therapeutics to address significant unmet medical needs and improve patient outcomes.
What's next for OxThera?
The substantial enterprise-level funding and recent strategic investment indicate OxThera is poised for significant scaling and advancement. This capital infusion is expected to accelerate the final stages of clinical trials, support regulatory submissions, and prepare for potential commercialization. The company's focus on a niche but significant rare disease area suggests a strategic push towards establishing a strong market presence and potentially expanding its therapeutic pipeline.
See full OxThera company page
